SOUTH SAN FRANCISCO, Calif., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today announced upcoming presentations of data from its lead program, plazomicin, at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC). The Company will present two posters at the event, which will be held in San Diego, from September 17th through September 21st.
Titles and details of posters to be presented by Achaogen are provided below.
| Presentation Title: Plazomicin, a Novel Aminoglycoside, Exhibits a Post-antibiotic Effect Against Enterobacteriaceae |
| Session Title: Pharmacokinetics/Pharmacodynamics (PK/PD) of New Drugs in Development |
| Poster Session: 006 |
| Poster Board #: A-052 |
| Date and Time: Friday, September 18, 2015 12:00 - 2:00 PM |
| Presentation Title: The Effect of In Vitro Testing Parameters on the MIC of Plazomicin |
| Session Title: Antimicrobial Susceptibility Testing Methods and Interpretation for Gram-Negative Pathogens |
| Poster Session: 013 |
| Poster Board #: D-183 |
| Date and Time: Friday, September 18, 2015 12:00 - 2:00 PM |
| An abstract summary of this poster will be featured at the ICAAC on-site press room for reporters who are covering the meeting. |
Plazomicin will also be the subject of three additional poster presentations during the meeting. These posters describe the activity of plazomicin against the following: 1) contemporary clinical isolates collected in USA hospitals (Achaogen-funded study performed by JMI Laboratories), 2) carbapenem-resistant Pseudomonas aeruginosa (University of Pittsburgh study), and 3) carbapenem non-susceptible Enterobacter (University of Pittsburgh study).
The abstracts can be accessed through the ICAAC website. Following the meeting, all posters presented by Achaogen will be available as PDF files on the Achaogen website at www.achaogen.com.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious lung, bloodstream, and urinary tract infections due to Enterobacteriaceae, including, but not limited to, carbapenem-resistant Enterobacteriaceae (CRE). Achaogen's plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen's gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.